ATE227726T1 - Thienopyrimidinderivate als endothelin antagonisten - Google Patents
Thienopyrimidinderivate als endothelin antagonistenInfo
- Publication number
- ATE227726T1 ATE227726T1 AT96926638T AT96926638T ATE227726T1 AT E227726 T1 ATE227726 T1 AT E227726T1 AT 96926638 T AT96926638 T AT 96926638T AT 96926638 T AT96926638 T AT 96926638T AT E227726 T1 ATE227726 T1 AT E227726T1
- Authority
- AT
- Austria
- Prior art keywords
- group
- prophylactic
- substituted
- denotes
- formula
- Prior art date
Links
- 102000002045 Endothelin Human genes 0.000 title 1
- 108050009340 Endothelin Proteins 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 title 1
- 229940043274 prophylactic drug Drugs 0.000 abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 206010002383 Angina Pectoris Diseases 0.000 abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 125000001183 hydrocarbyl group Chemical group 0.000 abstract 2
- 210000000056 organ Anatomy 0.000 abstract 2
- 230000000069 prophylactic effect Effects 0.000 abstract 2
- 229940126585 therapeutic drug Drugs 0.000 abstract 2
- 230000002792 vascular Effects 0.000 abstract 2
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 abstract 1
- 208000009304 Acute Kidney Injury Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 125000005915 C6-C14 aryl group Chemical group 0.000 abstract 1
- 206010007558 Cardiac failure chronic Diseases 0.000 abstract 1
- 229940118365 Endothelin receptor antagonist Drugs 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 208000003782 Raynaud disease Diseases 0.000 abstract 1
- 208000012322 Raynaud phenomenon Diseases 0.000 abstract 1
- 208000033626 Renal failure acute Diseases 0.000 abstract 1
- 208000032450 Surgical Shock Diseases 0.000 abstract 1
- 206010047139 Vasoconstriction Diseases 0.000 abstract 1
- 201000011040 acute kidney failure Diseases 0.000 abstract 1
- 208000012998 acute renal failure Diseases 0.000 abstract 1
- 150000001450 anions Chemical class 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 230000000747 cardiac effect Effects 0.000 abstract 1
- 206010008118 cerebral infarction Diseases 0.000 abstract 1
- 208000026106 cerebrovascular disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000007887 coronary angioplasty Methods 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000002308 endothelin receptor antagonist Substances 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 230000002685 pulmonary effect Effects 0.000 abstract 1
- 208000002815 pulmonary hypertension Diseases 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 206010040560 shock Diseases 0.000 abstract 1
- 125000006850 spacer group Chemical group 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- RBNBDIMXFJYDLQ-UHFFFAOYSA-N thieno[3,2-d]pyrimidine Chemical class C1=NC=C2SC=CC2=N1 RBNBDIMXFJYDLQ-UHFFFAOYSA-N 0.000 abstract 1
- 230000025033 vasoconstriction Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP20949895 | 1995-08-17 | ||
| PCT/JP1996/002290 WO1997007119A1 (en) | 1994-08-26 | 1996-08-13 | Thienopyrimidine derivatives, their production and use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE227726T1 true ATE227726T1 (de) | 2002-11-15 |
Family
ID=16573808
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT96926638T ATE227726T1 (de) | 1995-08-17 | 1996-08-13 | Thienopyrimidinderivate als endothelin antagonisten |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP0846119B1 (de) |
| AT (1) | ATE227726T1 (de) |
| AU (1) | AU6670196A (de) |
| CA (1) | CA2227384A1 (de) |
| DE (1) | DE69624829T2 (de) |
| WO (1) | WO1997007119A1 (de) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003531910A (ja) * | 2000-05-04 | 2003-10-28 | アストラゼネカ アクチボラグ | チエノ［２，３−ｄ］ピリミジンジオン類とそれらの医薬品としての使用 |
| GB201105659D0 (en) | 2011-04-01 | 2011-05-18 | Xention Ltd | Compounds |
| KR102172902B1 (ko) | 2011-11-11 | 2020-11-02 | 길리어드 아폴로, 엘엘씨 | Ａｃｃ 억제제 및 이의 용도 |
| AR106472A1 (es) | 2015-10-26 | 2018-01-17 | Gilead Apollo Llc | Inhibidores de acc y usos de los mismos |
| JP2019502660A (ja) | 2015-11-25 | 2019-01-31 | ギリアド アポロ， エルエルシー | ピラゾールａｃｃ阻害剤およびその使用 |
| HUE053175T2 (hu) | 2015-11-25 | 2021-06-28 | Gilead Apollo Llc | ACC-gátló észterek és azok alkalmazása |
| JP2019503338A (ja) | 2015-11-25 | 2019-02-07 | ギリアド アポロ， エルエルシー | ２，４−ジオキソ−１，４−ジヒドロチエノ［２，３−ｄ］ピリミジンの誘導体を含む殺真菌組成物 |
| JP2018536661A (ja) | 2015-11-25 | 2018-12-13 | ギリアド アポロ， エルエルシー | トリアゾールａｃｃ阻害剤およびその使用 |
| CA3155220C (en) | 2016-03-02 | 2024-01-16 | Gilead Apollo, Llc | Solid forms of a thienopyrimidinedione acc inhibitor and methods for production thereof |
| KR102743630B1 (ko) | 2017-03-28 | 2024-12-18 | 길리애드 사이언시즈, 인코포레이티드 | 간 질환을 치료하기 위한 치료 조합물 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2667294B2 (ja) * | 1991-11-05 | 1997-10-27 | スミスクライン・ビーチャム・コーポレイション | エンドセリン受容体拮抗剤 |
| TW276256B (de) * | 1993-08-26 | 1996-05-21 | Takeda Pharm Industry Co Ltd |
-
1996
- 1996-08-13 WO PCT/JP1996/002290 patent/WO1997007119A1/en not_active Ceased
- 1996-08-13 EP EP96926638A patent/EP0846119B1/de not_active Expired - Lifetime
- 1996-08-13 DE DE69624829T patent/DE69624829T2/de not_active Expired - Fee Related
- 1996-08-13 AU AU66701/96A patent/AU6670196A/en not_active Abandoned
- 1996-08-13 CA CA002227384A patent/CA2227384A1/en not_active Abandoned
- 1996-08-13 AT AT96926638T patent/ATE227726T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP0846119B1 (de) | 2002-11-13 |
| WO1997007119A1 (en) | 1997-02-27 |
| DE69624829D1 (de) | 2002-12-19 |
| DE69624829T2 (de) | 2003-07-31 |
| AU6670196A (en) | 1997-03-12 |
| EP0846119A1 (de) | 1998-06-10 |
| CA2227384A1 (en) | 1997-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0880502B1 (de) | Aminoheterocyclische verbindungen als antithrombotisches oder antikoagulierendes mittel | |
| JP2923742B2 (ja) | ４−アミノキナゾリン誘導体、その製造方法およびそれを含有する医薬品 | |
| KR950005311A (ko) | 티에노피리미딘 유도체, 그의 제조방법 및 용도 | |
| ATE227726T1 (de) | Thienopyrimidinderivate als endothelin antagonisten | |
| ATE161537T1 (de) | Kondensierte pyrimidinderivate und deren verwendung als angiotensin-ii-antagonisten | |
| US20090012087A1 (en) | New Aza-Bicyclohexane Compounds Useful As Inhibitors Of Thrombin | |
| JP5778133B2 (ja) | シクロプロパンカルボン酸誘導体 | |
| TW214542B (de) | ||
| JPWO1999052872A1 (ja) | インテグリンαＶβ３拮抗剤としてのアミノピペリジン誘導体 | |
| KR20010042587A (ko) | 인테그린 알파브이베타3 길항제로서 아미노피페리딘 유도체 | |
| NO982238D0 (no) | Substituerte 4-(1H-benzimidazol-2-yl-amino)piperidiner som er anvendbare for behandling av allergiske sykdommer | |
| HUP0202366A2 (en) | Pyrazinone thrombin inhibitors | |
| EP0777653B1 (de) | 1,4-dihydropyridine als bradykinin antagonisten | |
| Addicks et al. | Synthesis and Biological Investigation of Novel Tricyclic Benzodiazepinedione‐Based RGD Analogues | |
| CN116438175B (zh) | 苯并脲环衍生物及其制备方法和应用 | |
| HU198476B (en) | Process for producing piperidine derivatives and pharmaceutical compositions comprising such compounds | |
| CA2246727A1 (en) | Novel substituted n-methyl-n-(4-(piperidin-1-yl)-2-(aryl)butyl)benzamides useful for the treatment of allergic diseases | |
| US7265121B2 (en) | Chemical compounds | |
| OA10712A (en) | 1,4-Dihydropyridine compounds as bradykinin antagonists | |
| JPH1129569A (ja) | ４，５−ジヒドロ−［１Ｈ］−ベンズ［ｇ］インダゾール−３−カルボン酸誘導体 | |
| JP2023180347A (ja) | ハイブリッド型化合物又はその塩 | |
| JPS61225186A (ja) | ５−オクソ−ピリド〔４，３−ｄ〕ピリミジン誘導体、その製造方法および用途 | |
| CN101243069A (zh) | 凝血酶抑制剂2-氧代-1,2,5,6-四氢吡啶衍生物 | |
| JPS60123472A (ja) | アミノピリジンカルボン酸誘導体ならびに医薬組成物 | |
| NZ505887A (en) | Multi-binding compounds; useful as beta2-adrenergic receptor agonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |